Neurological Sciences

, Volume 32, Supplement 1, pp 105–109 | Cite as

New frontiers in headache therapy

Invited Lecture


There are numerous headache therapies available for our patients, more for migraine than for any of the other primary headache disorders. Only four medications have been approved for migraine prevention in the last few decades in the US and onabotulinumtoxinA was recently approved in the UK and the US for chronic migraine. We have been more fortunate in the acute care arena where in the US we have had seven triptans and one nonsteroidal anti-inflammatory medication approved by the FDA and currently available. There are several other acute care medications in various stages of development and there are two new methods of administering a triptan and others under investigation. We are always looking for faster, easier and more efficient administration of medications with fewer adverse events, as optimal migraine therapy requires these characteristics. What follows is a brief review of the progress in development for four of the many new acute care medications being investigated: the CGRP antagonist tablet telcagepant, the sumatriptan iontophoretic patch, sumatriptan powder for use in the OptiNose apparatus and the dihydroergotamine oral inhaler. I will not include transcranial magnetic stimulation, a 5-HT1F agonist, large conductance calcium-activated potassium channel openers, glial modulators or other medications and devices in early stages of development [1].


Migraine treatment Migraine pipeline CGRP antagonists Sumatriptan Dihydroergotamine 


Conflict of interest

A. Rapoport is on the Advisory Boards of NuPathe and MAP, an author of the Phase IIB study on telcagepant, and on the speakers bureau for Merck.


  1. 1.
    Ramadan NM, Buchanan TM (2006) New and future migraine therapy. Pharmacol Ther 112:199–212PubMedCrossRefGoogle Scholar
  2. 2.
    Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRefGoogle Scholar
  3. 3.
    Levy D, Burstein R, Strassman AM (2005) Calcitonin gene related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698–705PubMedCrossRefGoogle Scholar
  4. 4.
    Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRefGoogle Scholar
  5. 5.
    Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRefGoogle Scholar
  6. 6.
    Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089–2090CrossRefGoogle Scholar
  7. 7.
    Pierce M, Marbury T, O’Neill C et al (2008) A novel patch formulation of sumatriptan succinate utilizing SmartReliefTM transdermal technology. In: Data presented at the 50th annual scientific meeting of the American Headache Society, 28 June 2008Google Scholar
  8. 8.
    Rapoport AM, Freitag F, Pearlman S (2010) Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 24(11):929–940PubMedCrossRefGoogle Scholar
  9. 9.
    Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177–3187PubMedCrossRefGoogle Scholar
  10. 10.
    Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache 48:355–367PubMedCrossRefGoogle Scholar
  11. 11.
    Luthringer R, Djupesland PG, Sheldrake CD et al (2009) Rapid absorption of sumatriptan powder and effects on the glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 61:1–10. doi: 10.1211ISSN0022-3573 CrossRefGoogle Scholar
  12. 12.
    Djupesland PG, Docˇekal P, the Czech Migraine Investigators Group (2010) Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30(8):933–942 (Cephalalgia online first, published on March 17, 2010 as doi: 10.1177/0333102409359314)Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.David Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Director Emeritus of The New England Center for HeadacheStamfordUSA

Personalised recommendations